Molecular PCA3 diagnostics on prostatic fluid

Prostate

Volumn 67, Issue 8, 2007, Pages 881-887

  Van Gils, Martijn P M Q ^a   Cornel, Erik B ^b   Hessels, Daphne ^a   Peelen, W Pim ^a   Witjes, J Alfred ^a   Mulders, Peter F A ^a   Rittenhouse, Harry G ^c   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Urology   (Netherlands)

^c Gen Probe Incorporated   (United States)

Author keywords

Diagnosis; Human; Prostate cancer antigen 3; Prostatic fluid; Prostatic neoplasms; Urine

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CLINICAL RESEARCH; DIAGNOSTIC TEST; DIGITAL RECTAL EXAMINATION; EVALUATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PCA3 TEST; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ANTIGENS, NEOPLASM; BIOPSY; BODY FLUIDS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE;

EID: 34249685906     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20564     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. version 2.0, Lyon, France: IARCPress; 2004.
3. van Gils MP, Stenman UH, Schalken JA, Schroder FH, Luider TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KS, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 2005; 48:1031-1041.
4. Crocitto LE, Korns D, Kretzner L, Shevchuk T, Blair SL, Wilson TG, Ramin SA, Kawachi MH, Smith SS. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 2004;64:821-825.
5. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 2004;4:513-526.
6. Hessels D, Rittenhouse HG, Schalken JA. Molecular diagnostics in prostate cancer. EAU Update Ser 2005;3:200-213.
7. Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, Mukhtar H. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 1999;5:143-147.
8. Muller H, Brenner H. Urine markers as possible tools for prostate cancer screening: Review of performance characteristics and practicality. Clin Chem 2006;52:562-573.
9. Perk H, Serel TA, Delibas N, Sutcu R. Prostatic fluid-free insulin-like growth factor-1 in relation to prostate cancer. BJU Int 2001;88:946-949.
10. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. Clin Cancer Res 2004;10:3943-3953.
11. Wang Z, Ramin SA, Tsai C, Lui P, Herbert PJ, Kyeyune-Nyombi E, Ruckle HC, Beltz RE, Sands JF. Detection of telomerase activity in prostatic fluid specimens. Urol Oncol 2000;6:4-9.
12. Wang Z, Ramin SA, Tsai C, Lui P, Ruckle HC, Beltz RE, Sands JF, Slattery CW. Evaluation of PCR-ELISA for determination of telomerase activity in prostate needle biopsy and prostatic fluid specimens. Urol Oncol 2002;7:199-205.
13. Wilson MJ, Haller R, Li SY, Slaton JW, Sinha AA, Wasserman NF. Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: Possible prostate cancer disease marker. J Urol 2005; 174:1124-1128.
14. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-5979.
15. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-2698.
16. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van BB, Kiemeney LA, Witjes JA, Schalken JA. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
17. Meng FJ, Shan A, Jin L, Young CY. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev 2002;11:305-309.
18. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Masse B, Piche L, Chypre C. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-315.
19. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine - A new perspective for detecting prostate cancer. Eur Urol 2004;46:182-186.
20. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-1095.